Efficacy and specificity of inhibitors of BCL-2 family protein interactions assessed by affinity measurements in live cells
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy and specificity of inhibitors of BCL-2 family protein interactions assessed by affinity measurements in live cells
Authors
Keywords
-
Journal
Science Advances
Volume 8, Issue 16, Pages -
Publisher
American Association for the Advancement of Science (AAAS)
Online
2022-04-21
DOI
10.1126/sciadv.abm7375
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax
- (2020) Piers Blombery et al. BLOOD
- Allosteric Regulation of BH3 Proteins in Bcl-xL Complexes Enables Switch-like Activation of Bax
- (2020) Christian Bogner et al. MOLECULAR CELL
- The carboxyl-terminal sequence of bim enables bax activation and killing of unprimed cells
- (2020) Xiaoke Chi et al. eLife
- The Bcl-2 Family: Ancient Origins, Conserved Structures, and Divergent Mechanisms
- (2020) Suresh Banjara et al. Biomolecules
- Discovery of A-1331852, a First-in-Class, Potent and Orally-Bioavailable BCL-XL Inhibitor
- (2020) Le Wang et al. ACS Medicinal Chemistry Letters
- Unroofing site-specific α-synuclein–lipid interactions at the plasma membrane
- (2020) Upneet Kaur et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A novel recombinant expression and purification approach for the full-length anti-apoptotic membrane protein Bcl-2
- (2020) Jörgen Ådén et al. PROTEIN EXPRESSION AND PURIFICATION
- How to measure and evaluate binding affinities
- (2020) Inga Jarmoskaite et al. eLife
- AZD4320, a dual inhibitor of Bcl-2 and Bcl-xL, induces tumor regression in hematological cancer models without dose-limiting thrombocytopenia
- (2020) Srividya B Balachander et al. CLINICAL CANCER RESEARCH
- Highly Multiplexed Confocal Fluorescence Lifetime Microscope Designed for Screening Applications
- (2020) Nehad Hirmiz et al. IEEE JOURNAL OF SELECTED TOPICS IN QUANTUM ELECTRONICS
- The Structural Biology of Bcl-xL
- (2019) Erinna F. Lee et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Bim escapes displacement by BH3-mimetic anti-cancer drugs by double-bolt locking both Bcl-XL and Bcl-2
- (2019) Qian Liu et al. eLife
- BH3 profiling discriminates on-target small molecule BH3 mimetics from putative mimetics
- (2019) Mariana Villalobos-Ortiz et al. CELL DEATH AND DIFFERENTIATION
- Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations
- (2019) Richard W. Birkinshaw et al. Nature Communications
- MCL-1 inhibitors – where are we now (2019)?
- (2019) Steven Fletcher EXPERT OPINION ON THERAPEUTIC PATENTS
- FRET as a biomolecular research tool — understanding its potential while avoiding pitfalls
- (2019) W. Russ Algar et al. NATURE METHODS
- S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth
- (2018) Patrick Casara et al. Oncotarget
- Fit-free analysis of fluorescence lifetime imaging data using the phasor approach
- (2018) Suman Ranjit et al. Nature Protocols
- BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment
- (2018) Patricia Gomez-Bougie et al. BLOOD
- Venetoclax for the treatment of chronic lymphocytic leukemia
- (2017) Massimo Gentile et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells
- (2016) Sina Oppermann et al. BLOOD
- Loss of PUMA (BBC3) does not prevent thrombocytopenia caused by the loss of BCL-XL (BCL2L1)
- (2016) Alex R. D. Delbridge et al. BRITISH JOURNAL OF HAEMATOLOGY
- Metabolism and Disposition of a Novel B-Cell Lymphoma-2 Inhibitor Venetoclax in Humans and Characterization of Its Unusual Metabolites
- (2016) Hong Liu et al. DRUG METABOLISM AND DISPOSITION
- BCL2 Inhibitors as Anticancer Drugs: A Plethora of Misleading BH3 Mimetics
- (2016) R. S. Soderquist et al. MOLECULAR CANCER THERAPEUTICS
- Quantifying macromolecular interactions in living cells using FRET two-hybrid assays
- (2016) Elisabeth S Butz et al. Nature Protocols
- Screening for protein-protein interactions using Förster resonance energy transfer (FRET) and fluorescence lifetime imaging microscopy (FLIM)
- (2016) Anca Margineanu et al. Scientific Reports
- Tight Sequestration of BH3 Proteins by BCL-xL at Subcellular Membranes Contributes to Apoptotic Resistance
- (2016) Jessie Pécot et al. Cell Reports
- NanoBRET—A Novel BRET Platform for the Analysis of Protein–Protein Interactions
- (2015) Thomas Machleidt et al. ACS Chemical Biology
- Conformation of BCL-XL upon Membrane Integration
- (2015) Yong Yao et al. JOURNAL OF MOLECULAR BIOLOGY
- Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy
- (2015) Joel D. Leverson et al. Science Translational Medicine
- Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma
- (2014) V. Fresquet et al. BLOOD
- Functions of the C-terminal domains of apoptosis-related proteins of the Bcl-2 family
- (2014) Juan C. Gómez-Fernández CHEMISTRY AND PHYSICS OF LIPIDS
- BM-1197: A Novel and Specific Bcl-2/Bcl-xL Inhibitor Inducing Complete and Long-Lasting Tumor Regression In Vivo
- (2014) Longchuan Bai et al. PLoS One
- Noxa determines localization and stability of MCL-1 and consequently ABT-737 sensitivity in small cell lung cancer
- (2014) W Nakajima et al. Cell Death & Disease
- Systems Analysis of BCL2 Protein Family Interactions Establishes a Model to Predict Responses to Chemotherapy
- (2013) A. U. Lindner et al. CANCER RESEARCH
- Novel Small-Molecule Inhibitors of Bcl-XL to Treat Lung Cancer
- (2013) D. Park et al. CANCER RESEARCH
- Measuring protein interactions using Förster resonance energy transfer and fluorescence lifetime imaging microscopy
- (2013) Richard N. Day METHODS
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
- (2013) Andrew J Souers et al. NATURE MEDICINE
- Interactions of pro-apoptotic BH3 proteins with anti-apoptotic Bcl-2 family proteins measured in live MCF-7 cells using FLIM FRET
- (2012) Qian Liu et al. CELL CYCLE
- Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer
- (2012) C. M. Rudin et al. CLINICAL CANCER RESEARCH
- Design of Bcl-2 and Bcl-xL Inhibitors with Subnanomolar Binding Affinities Based upon a New Scaffold
- (2012) Haibin Zhou et al. JOURNAL OF MEDICINAL CHEMISTRY
- Differences in the Mechanisms of Proapoptotic BH3 Proteins Binding to Bcl-XL and Bcl-2 Quantified in Live MCF-7 Cells
- (2012) Alexander Aranovich et al. MOLECULAR CELL
- FLIM FRET Technology for Drug Discovery: Automated Multiwell-Plate High-Content Analysis, Multiplexed Readouts and Application in Situ
- (2011) Sunil Kumar et al. CHEMPHYSCHEM
- Noxa/Bcl-2 Protein Interactions Contribute to Bortezomib Resistance in Human Lymphoid Cells
- (2011) Alyson J. Smith et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- An Improved Cerulean Fluorescent Protein with Enhanced Brightness and Reduced Reversible Photoswitching
- (2011) Michele L. Markwardt et al. PLoS One
- Bcl-2 proteins and mitochondria—Specificity in membrane targeting for death
- (2010) Jennefer Lindsay et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Individual and overlapping roles of BH3-only proteins Bim and Bad in apoptosis of lymphocytes and platelets and in suppression of thymic lymphoma development
- (2010) P N Kelly et al. CELL DEATH AND DIFFERENTIATION
- Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
- (2010) Wyndham H Wilson et al. LANCET ONCOLOGY
- Still embedded together binding to membranes regulates Bcl-2 protein interactions
- (2010) B Leber et al. ONCOGENE
- Bid: a Bax-like BH3 protein
- (2009) L P Billen et al. ONCOGENE
- ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
- (2008) C. Tse et al. CANCER RESEARCH
- Expression and purification of recombinant annexin V for the detection of membrane alterations on apoptotic cells
- (2008) Gabriela Brumatti et al. METHODS
- Bcl-XL Inhibits Membrane Permeabilization by Competing with Bax
- (2008) Lieven P Billen et al. PLOS BIOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now